Abbott Tricor adds tablets with HDL indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Tricor (fenofibrate) is approved Sept. 5 in two tablet strengths, 54 mg and 160 mg. Abbott's lipid-lowering agent was launched in 1998 as a 67 mg micronized capsule for treatment of type II, IV, and V hyperlipidemia and is also available as 134 mg and 200 mg capsules. The tablet formulation received approval for an additional claim that the capsule does not have: increasing HDL cholesterol in patients with primary hypercholesterolemia or mixed dyslipidemia, according to the company